ReviewThe Indian journal of tuberculosis2021
Post covid 19 pulmonary fibrosis. Is it real threat?
Review in The Indian journal of tuberculosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07380152 (Corticosteroid Treatment for Post-COVID-19 Persistent Interstitial Lung Disease), which is not on this map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Corticosteroid Treatment for Post-COVID-19 Persistent Interstitial Lung Disease
Who cites it
76 citing papers in PubMed, 155 citations in OpenAlex.
- Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study.Medicina clinica · 2023Trial
- Serum Mammalian Target of Rapamycin (mTOR) Levels in Patients with Post-COVID-19 Fibrotic-like Lung Changes: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Development and Validation of a CT-based Deep Transfer Learning Radiomic Model for Predicting Post-COVID-19 Pulmonary FibrosisCurrent medical imaging · 2026Article
- Progressive fibrotic interstitial lung diseases in India: national challenges and implications for global health policies.Health research policy and systems · 2025Review
- A collaborative study on rehabilitating altered pulmonary functions of COVID-19 survivors with selective yoga regime.Journal of family medicine and primary care · 2025Article
- Presence and Evolution of Radiological Changes at 6 and 12 Months After COVID-19 Pneumonia and Their Risk Factors.Medicina (Kaunas, Lithuania) · 2025Article
- Impact of underlying diseases and complications on COVID-19 mortality in South Korea: analysis of national health insurance service data.Archives of public health = Archives belges de sante publique · 2025Article
- Article
- Predictors of the presence of radiological abnormalities 6 months after severe COVID-19 pneumonia.BMC infectious diseases · 2024Article
- Article
- Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America.International journal of environmental research and public health · 2024Article
- Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems.AAPS PharmSciTech · 2024Review
- Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers.International journal of molecular sciences · 2024Review
- The Multisystem Impact of Long COVID: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Quantification of fibrosis extend and airspace availability in lung: A semi-automatic ImageJ/Fiji toolbox.PloS one · 2024Article
- An agent-based modeling approach for lung fibrosis in response to COVID-19.PLoS computational biology · 2023Article
- Intensive care nurse-led point of care ultrasound in the assessment and management of the critically ill COVID-19 patient: A single centre case series.Nursing in critical care · 2023Article
- Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review.Pulmonary therapy · 2023Review
- Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study.Medicina clinica (English ed.) · 2023Article
- Clinicopathological Outlines of Post-COVID-19 Pulmonary Fibrosis Compared with Idiopathic Pulmonary Fibrosis.Biomedicines · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After the COVID-19 outbreak, increasing number of patients worldwide who have survived COVID-19 continue to battle the symptoms of the illness, long after they have been clinically tested negative for the disease. As we battle through this pandemic, the challenging part is to manage COVID-19 sequelae which may vary from fatigue and body aches to lung fibrosis. This review addresses underlying mechanism, risk factors, course of disease and treatment option for post covid pulmonary fibrosis. Elderly patient who require ICU care and mechanical ventilation are at the highest risk to develop lung fibrosis. Currently, no fully proven options are available for the treatment of post inflammatory COVID 19 pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.